StemRIM
Notice of US Patent Registration for Stem Cell Gene Therapy Technology for Recessive Dystrophic Epidermolysis Bullosa (Development Code: SR-GT1)
A patent for a treatment for recessive dystrophic epidermolysis bullosa is expected to be registered in the US. SR-GT1 is a therapy using autologous mesenchymal stem cells with introduction of a normal type VII collagen gene to achieve long-term engraftment. Impact on the fiscal year ending July 2027 is unknown, but preparations for clinical application are underway with AMED support.
Key Figures
- Patent registration region: US
- Application number: 17/423,285
- Registration number: 12751974
AI要約
News Overview
This announcement informs that a US patent related to the company's stem cell gene therapy technology SR-GT1 is scheduled for registration. The patent pertains to the administration of therapeutic cells and is part of a treatment approach being advanced toward clinical application under the regenerative induction pharmaceuticals framework based on collaborative research with Osaka University. Attention is expected to focus on future development progress.
Outlook and Impact
With AMED support, manufacturing of the investigational drug for clinical use is progressing with a view to clinical application, and preparations to transition to physician-led clinical trials are steadily advancing. However, this matter is not expected to affect full-year results for the fiscal year ending July 2027, and any additional disclosures will be announced promptly. For investors, this is information to monitor for the potential long-term establishment of a therapy and market creation.
StemRIM
Company overview · Stock price · Financial data · All IR
